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Abstract Pseudoxanthoma elasticum (PXE) is a heritable
disorder characterized by ectopic calcification of connective
tissue in skin, Bruch’s membrane of the eye, and walls of
blood vessels. PXE is caused by mutations in the ABCC6
gene, but the exact etiology is still unknown. While
observations on patients suggest that high calcium intake
worsens the clinical symptoms, the patient organization
PXE International has published the dietary advice to
increase calcium intake in combination with increased
magnesium intake. To obtain more data on this controver-
sial issue, we examined the effect of dietary calcium and
magnesium in the Abcc6
−/− mouse, a PXE mouse model
which mimics the clinical features of PXE. Abcc6
−/− mice
were placed on specific diets for 3, 7, and 12 months.
Disease severity was measured by quantifying calcification
of blood vessels in the kidney. Raising the calcium content
in the diet from 0.5% to 2% did not change disease severity.
In contrast, simultaneous increase of both calcium (from
0.5% to 2.0%) and magnesium (from 0.05% to 0.2%)
slowed down the calcification significantly. Our present
findings that increase in dietary magnesium reduces
vascular calcification in a mouse model for PXE should






Pseudoxanthoma elasticum (PXE) is a connective tissue
disease characterized by progressive mineralization and
fragmentation of elastic fibers [1–3]. Clinical manifesta-
tions generally appear in the second or third decade of life
and occur mainly in skin, eye, and blood vessels. In the
skin, PXE is characterized by papules and plaques typically
present in the neck and in flexural areas. The eye of PXE
patients can develop angioid streaks, which represent
breaks in Bruch’s membrane. Through these breaks, neo-
vascularization occurs with subsequent hemorrhages, which
lead to acute, irreversible loss of vision. Cardiovascular
symptoms of PXE include calcification of blood vessels
and bleedings in internal organs. The prevalence of PXE is
estimated to be between 1:25,000 and 1:100,000 [4].
PXE inherits in an autosomal recessive fashion [5]. In
2000, the causative gene was identified as ABCC6, a member
of the large family of ATP-binding cassette transporters
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DOI 10.1007/s00109-010-0596-3[6, 7]. Mutation analysis [8, 9] and in vitro transport studies
with PXE-related ABCC6 mutants [10] indicate that PXE is
primarily caused by loss of the transport activity of the
encoded protein. ABCC6 is highly expressed in liver and
kidney [11]. In the liver, the protein is located in the
basolateral membrane of the hepatocyte, which suggests that
its substrate is transported from the hepatocyte cytoplasm
into the bloodstream. The physiological substrate of the
transporter remains as yet elusive. Remarkably, the organs
affected in PXE show little or no expression of the protein,
which suggests that PXE is a systemic disease caused by
changes in blood composition when ABCC6 transport
function is deficient [12].
To investigate the biological function of ABCC6, we and
others have disrupted the homologous gene in the mouse
[13, 14]. Abcc6
−/− mice readily develop ectopic calcifica-
tion in the walls of blood vessels. At advanced age, also
Bruch’s membrane of the eye and the skin become
mineralized. Thus, Abcc6 deficiency in the mouse essen-
tially re-creates the clinical features of PXE. This confirms
that mutations in ABCC6 cause PXE. It also indicates that
the Abcc6
−/− mouse is a suitable animal model for studies
on etiology and treatment of PXE.
While serum ion balance is not altered in PXE, several
studies on patients suggest that mineral intake influences
disease severity in PXE. First, Renie et al. found, after
examination of 32 unrelated PXE cases, that clinical
severity correlated positively with calcium ingestion [15].
Second, Martinez-Hernandez and colleagues observed
regression of the calcification in the dermis in a PXE
patient upon reduction of calcium intake [16]. Finally, a
case report [17] described that normalization of the serum
calcium–phosphate product resulted in regression of the
skin lesions in a patient with chronic renal failure. These
studies suggested that restriction of dietary calcium intake
may be beneficial for PXE patients. However, this has not
led to a general advice to PXE patients to restrict dietary
calcium intake. Reducing serum calcium levels is difficult
to achieve, as the supply of the calcium from the bones is
practically unlimited. Moreover, reducing calcium intake
may have the negative side effect of osteoporosis. Indeed,
the patient organization PXE International has given PXE
patients the advice to increase calcium intake in combina-
tion with increased magnesium intake [18]. While this
dietary advice allegedly has been of value in treatment of
kidney stones [18], there is currently no evidence that this
diet is beneficial for PXE patients.
In the present study, we used the Abcc6
−/− mouse model
to obtain experimental data on the putative effects of
dietary calcium and magnesium on PXE pathology. The
results presented here show that dietary magnesium
influences the development of pathology in this animal
model for PXE, whereas calcium does not.
Materials and methods
Mice and diets
Generation and PCR-mediated genotyping of the Abcc6
−/−
mice has been described [13]. Abcc6
−/− mice were
generated in a hybrid background of C57Bl/6-129/ola and
then backcrossed to C57Bl/6. The genetic background of the
Abcc6
−/− and wild-type mice used in the present experi-
ment was backcross number 5. After weaning, female
Abcc6
−/− and wild-type mice were fed one of three custom
designed diets, which differed in calcium and magnesium
concentration. We first designed a “baseline” diet, which
contained the Ca and Mg nutrient requirements for health
and maximal growth, which are 0.5% (w/w) Ca and 0.05%
(w/w)M g[ 19]. In addition, this Ca and Mg content
corresponds to the formulation of the standard purified
rodent diet AIN-93. Next, in view of the reports which
suggested that high calcium intake aggravates PXE, we
designed a “4×Ca” diet, with four times increased calcium
content: 2% Ca. Finally, following the advice of PXE
International [18], the third diet was supplemented with
both Ca and Mg. This “4×Ca, 4×Mg” diet contained a
fourfold increased calcium and magnesium (2% Ca and
0.2% Mg). All other ingredients were kept the same for all
three diets (Table 1). P for example was kept at 0.5%. Diets
were purchased from Harlan Teklad (Madison, Wi, USA).
In this study, we employed 58 Abcc6
−/− mice and 58
wild-type mice, five to nine mice per genotype, diet, and
diet duration. Mice were kept in a controlled environment
with food and water ad libitum and a 12-h light/dark cycle
with light intensity of 70–90 lx. They were checked
regularly for general parameters of well-being, and their
weight was measured. All animal studies were approved by
an independent animal ethical committee (Dutch equivalent
of the IACUC).
The diets were given for 3, 7, or 12 months. At the end
of the diet period, the mice were killed. At 9:00 A.M., the
food was removed, and after fasting for 6–8 h, mice were
killed by CO2/O2 inhalation and decapitated, and blood was
collected in tubes containing heparin. Plasma was obtained
after centrifugation and stored at −80°C. Plasma values
were determined by the clinical laboratory of the Academic
Medical Center, University Hospital of Amsterdam, follow-
ing standard procedures and assays (Roche Diagnostics).
The following plasma parameters were measured: calcium,
magnesium, phosphate, iron (all by colorimetric assays),
HDL-cholesterol,creatinine,urea(byenzymaticassays),and
total protein (biuret assay).
For histopathology, heart and kidney were collected and
fixed in 2% paraformaldehyde in 0.1 M phosphate buffer and
embeddedinparaffin.Sectionswerestainedwithhematoxylin–
eosin and von Kossa using standard procedures.
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We quantified the calcification of blood vessels in the
cortex of the kidney with the use of histology. Sagittal
sections of 6 μm were cut from the kidney and stained for
calcification according to von Kossa. For quantification, we
examined five sections per mouse, each separated by
180 μm. We counted the number of von Kossa positive
blood vessel profiles in the kidney cortex and calculated the
average number per section. Von Kossa positive structures
in the pelvis, tubules, or in adjacent adipose tissue were
excluded.
Micrographs were taken with a Zeiss Axioplan 2 (Carl
Zeiss AG, Germany) equipped with an Evolution MP
camera (MediaCybernetics, Bethesda, USA) and Image-Pro
Plus acquisition software (version 6, MediaCybernetics,
Bethesda, USA). A ×5 and a ×20 Plan apo achromat
objective lens with 0.16, respectively, 0.60 numerical
aperture were used. Image processing was done with
Adobe Photoshop (Adobe Systems Inc., USA).
Measurement of calcification in the heart
Calcification of the heart was quantified using µCTscans of
hearts that had been fixed with paraformaldehyde and
embedded in paraffin. The hearts were scanned in a
Skyscan 1072 µCT scanner (Skyscan, Kontich, Belgium)
at X-ray source settings of 80 kV and 100 mA, resulting in
three-dimensional data sets with an isotropic voxel size of
7.8 µm. Noise in the data sets was reduced using Gaussian
filtering with a base of 5 and a standard deviation of one
voxel. Calcifications were separated from the soft tissue of
the heart using a global threshold at a gray value of 190.
Using Matlab (The Mathworks Inc., Natick, MA, USA), all
calcifications were counted and their size was measured.
Calcifications of one voxel were considered to be artifacts
caused by imaging noise and removed from the analysis.
Statistics
A one-way ANOVAwas used to determine the independent
effects of genotype, diet, and diet duration on the various
parameters measured. Significance was accepted at p<0.05.
In case of statistical significance, the ANOVAwas followed
by a post hoc test of Student–Newman–Keuls. Since the
number of calcifications in blood vessels of the kidney cortex
did not show a normal distribution, we used the non-
parametric Kruskal–Wallis test (followed by Mann–Whitney
U test) to analyze the effect of diet on the number of
calcifications in blood vessels of the kidney at 3, 7, and
12 months of diet. In addition, for determining correlation
between parameters, Spearman’sr h ow a sc a l c u l a t e d .
Table 1 Composition of the diets
Baseline diet
(0.5% Ca and 0.05% Mg)
4×Ca diet
(2% Ca and 0.05% Mg)
4×Ca, 4×Mg diet
(2% Ca and 0.2% Mg)
g/kg
Casein 200.0 200.0 200.0
DL-Methionine 3.0 3.0 3.0
Corn starch 374.83 337.43 337.43
Maltodextrin 130.0 130.0 130.0
Sucrose 130.0 130.0 130.0
Soybean oil 60.0 60.0 60.0
Cellulose 40.0 40.0 40.0
Vitamin mix, AIN-93-VX (TD 94047) 15.0 15.0 15.0
Choline bitartrate 3.0 3.0 3.0
Vitamin K, phylloquinone 0.005 0.005 0.005
Tert-butylhydroquinone 0.025 0.025 0.025
Mineral Mix, AIN-93G-MX (TD 94046) 35.0 35.0 35.0
Potassium phosphate, monobasic, KH2PO4 8.8 8.8 8.8
Ferric citrate 0.3 0.3 0.3
Manganous carbonate 0.03 0.03 0.03
Cupric carbonate 0.01 0.01 0.01
Calcium carbonate, CaCO3 37.4 37.4
Magnesium oxide, MgO 2.55
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Diet schedule
To examine the effect of dietary calcium and magnesium
concentrations on PXE pathology, we put Abcc6
−/− and
wild-type mice on one of three custom diets: the baseline
diet (0.5% Ca and 0.05% Mg), 4×Ca diet (2% Ca and
0.05% Mg), and the 4×Ca, 4×Mg diet (2% Ca and 0.2%
Mg). The diets were started immediately after weaning, at
4 weeks after birth, and lasted for 3, 7, or 12 months. None
of the diets had overt adverse effects on behavior or well-
being of the mice. In addition, no significant weight
differences were found between the genotypes.
Diet mineral content influences blood vessel calcification
in the kidney
Since calcification of blood vessels is a prominent clinical
feature both of PXE patients [1] and Abcc6
−/− mice [13],
we measured this parameter in the mouse as function of the
diets. Histology was used to quantify calcification of small
arteries in the cortex of the kidney (Fig. 1).
Wild-type mice hardly developed calcifications in the
kidney. In only four of the 58 wild-type mice examined, we
detected calcified blood vessels. Two of these mice had
received the baseline diet for 12 months; the other two mice
had received the 4×Ca diet for 12 months. The low number
of calcifications in wild-type mice precluded statistical
analysis of possible differential effects of the diets.
In contrast with wild-type mice, Abcc6
−/− mice readily
developed calcifications. When fed the baseline diet,
calcifications were already found after 3 months (about
one per section), and this increased to 18 per section after
12 months (Fig. 2). Surprisingly, supplementation of the
diet with calcium did not increase the calcification. In
contrast, simultaneous supplementation with both Ca and
Mg slowed down the calcification significantly (compared
to baseline diet or 4×Ca diet after 3, 7, and 12 months;
Kruskal–Wallis test, p<0.05). After 12 months of the 4×Ca,
4×Mg diet, the number of calcifications was less than one
third of that in the other diet groups.
MicroCT scans of the heart confirm the effect
of dietary magnesium
To confirm and extend our finding that dietary Mg
modulates ectopic calcification, we employed μCT to
measure calcification in the hearts of the mice. Since the
calcifications were most abundant after 12 months of diet,
we performed this analysis at this time point. The μCT
scans revealed multiple calcifications localized mostly in
the ventricles (Fig. 3b, c). These calcifications had an
Fig. 1 Light micrographs of sections of the kidney cortex of a wild-
type (a) and an Abcc6
−/− mouse (b, with detail in c), stained for
calcification with von Kossa. The mice were killed after 12 months of
a diet supplemented with Ca (4×Ca diet). Extensive calcification
(black deposits) is present in arteries in the kidney cortex of the
Abcc6
−/− mouse (b). Please notice that the calcification is located
within the wall of the artery (arrows in b and c, which shows a detail
of b). Bar represents 100 μm
470 J Mol Med (2010) 88:467–475average size of 10
5 μm
3. Histology localized them in walls
of blood vessels (Fig. 4). In agreement with the findings in
the kidney, the 4×Ca, 4×Mg diet reduced calcification as
compared to the 4×Ca diet (on average 17 vs. 51 per heart;
Fig. 5). This underscores that dietary magnesium modulates
calcification in this PXE mouse model.
Analysis of plasma parameters
In order to assess possible systemic consequences of the
diets, we collected fasting blood of the mice at sacrifice and
measured several plasma parameters. Using ANOVA, we
analyzed the influence of genotype, diet, and diet duration
(cq. age) on these parameters. In addition, we determined
whether there was a correlation of these values with disease
severity as reflected in the number of calcifications in
kidney blood vessels.
The plasma levels of the minerals examined (Ca, PO4,
Mg, and Fe) did not significantly depend on genotype. In
contrast, the choice of diet caused significant changes in
plasma Ca and Mg levels. Mice fed with extra calcium had
higher plasma levels of calcium. Extra magnesium in the
food led to higher plasma Mg levels. However, these
changes were small and were not statistically significant at
all time points (see Table 2 for Abcc6
−/− mice after
7 months of diet). In addition, no correlation was observed
between the levels of these minerals and the extent of
calcification in the kidney. For example, Spearman’s
correlation coefficient between plasma Mg levels and
kidney calcification in Abcc6
−/− mice was −0.189 (P value
0.501) after 7 months of diet and 0.228 (P value 0.320)
after 12 months of diet. PO4 and Fe levels did not change
significantly by diet.
Since calcifications in kidney blood vessels may affect
kidney function, we measured plasma indicators of kidney
function. Chronic renal dysfunction is among others
associated with elevated plasma levels of urea, creatinine,
and total protein. We found no significant effect of
genotype on the levels of these parameters. Apparently, in
none of the diet groups, the kidney calcifications caused a
measurable decrease in kidney function. In addition, no
correlation was found between these plasma values and
kidney blood vessel calcifications.
In a previous study, we found that HDL-cholesterol
levels were decreased in Abcc6
−/− mice. In the present
study, Abcc6
−/− mice again had reduced plasma HDL-
cholesterol levels (for all Abcc6
−/− mice vs. wild-type mice:
8.55 vs. 11.57 mmol/L, p=0.04). However, the HDL-
cholesterol levels did not depend on the diet, and no
correlation existed between decreased HDL-cholesterol
levels and increased kidney calcification.
Fig. 3 Calcification in the heart
analyzed by μCT. a, b
Reconstructed μCT cross-
section of the heart of a wild-
type (a) and an Abcc6
−/− mouse
(b) killed after 12 months of
4×Ca diet. Please notice in the
Abcc6
−/− mouse the white dots
(arrows) representing the X-ray
opaque calcifications in the
ventricle wall. c Three-
dimensional reconstruction of
the μCT scan of this Abcc6
−/−
mouse, showing the distribution
of the calcifications (white dots)
in the heart
Fig. 2 Effect of diet on the number of calcifications in blood vessels
in the kidney cortex of Abcc6
−/− mice. Histograms represent the
average number of calcifications per kidney section as function of diet
and diet duration. At each diet duration, the diet supplemented with
Ca and Mg (4×Ca, 4×Mg diet) caused less calcifications than the other
diets (Kruskal–Wallis test, P<0.05)
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The clinical expression of PXE is remarkably variable even
between patients that share exactly the same ABCC6
mutation [8]. This implies that other factors contribute to
PXE pathology, including perhaps dietary factors [20]. The
aim of the present study was to investigate in our mouse
model for PXE whether we could influence age of onset,
progression, and severity of the pathology by mineral
intake. The clinical relevance of this research question is
obvious as presymptomatic DNA diagnosis for PXE is
possible, and mineral intake can be easily modified by PXE
patients themselves.
The use of the animal model has the advantage that all
experimental factors can be controlled. The Abcc6
−/−
mouse develops calcification in the skin, eye, and cardio-
vascular system and thus essentially recapitulates all
clinical features of PXE [13, 14]. While in PXE patients
the involvement of the various organs (skin, eye, and
cardiovascular system) is highly variable [8], in the
Abcc6
−/− mouse, the vascular calcification is the most
prominent feature. The skin and eye pathology develop in
the Abcc6
−/− mouse only at advanced age. In the present
study, we therefore focused on the cardiovascular aspect of
PXE, which we quantified in the kidney by histology and in
the heart by μCT scan.
In addition to the Abcc6
−/− mouse, another mouse model
recently became relevant for PXE as well. A number of
inbred mouse strains are very susceptible to dystrophic
cardiac calcinosis (DCC), which refers to a spontaneous
peri/myocardial calcification. This calcification occurs in
the presence of normal calcium and phosphate levels [21].
In 2007, Meng and coworkers demonstrated that Abcc6 is
the major causative gene for DCC as they rescued the
calcification phenotype in DBA mice by transgenic
complementation with a BAC uniquely containing Abcc6.
DCC susceptible strains reportedly have an alternative
splice variant, which leads to ABCC6 protein deficiency
[22]. Interestingly, a number of studies have already been
done on the influence of diet on DCC.
Ca intake does not influence vascular calcification
in the Abcc6
−/− mouse
The first factor which we investigated was the calcium
concentration in the food. Previous observations on PXE
patients suggested that high calcium intake increased the
severity of disease [15–17]. We examined the effect of a
fourfold increase in dietary calcium over a period of up to
1 year. In this period, we noticed small increases in plasma
calcium concentration. Most importantly, however, severity
and pace of soft tissue calcification did not change. This
Fig. 5 Histogram of the number of calcifications (±SD) in the heart,
determined by μCT, as function of the diet. The 4×Ca diet caused
more calcifications than the 4×Ca, 4×Mg diet (t test, P<0.05). Diet
duration was 12 months
Fig. 4 a Micrographs of
paraffin sections of the ventricle
of the heart of a wild-type (a)
and an Abcc6
−/− mouse (b). Von
Kossa staining demonstrates
calcifications (black deposits;
arrows) in walls of arteries in
the Abcc6
−/− mouse. Bar is
50 μm
472 J Mol Med (2010) 88:467–475indicates that, within the range of the calcium concen-
trations used, the vascular calcification in the Abcc6
−/−
mouse does not depend on Ca intake. These results
certainly do not provide a justification to diminish PXE
patient Ca intake.
Mg intake does influence vascular calcification
in the Abcc6
−/− mouse
The next dietary mineral we tested was magnesium, since
there are indications that this mineral influences soft tissue
calcification [23]. Moreover, a dietary advice has been
given to PXE patients to increase magnesium intake along
with increased calcium intake [18]. In agreement with this
advice, we found that a fourfold increase in both Ca and
Mg concentration reduced blood vessel calcification in our
PXE mouse model. This effect was clearly caused by the
magnesium concentration since the fourfold increase of
calcium alone did not produce this effect.
Recently, LaRusso and coworkers [24] evaluated the
effect of dietary magnesium in a different, but highly
comparable Abcc6 knockout mouse [14]. Their experimen-
tal setup consisted of a diet period of 8 weeks, and
calcification was measured in the capsule surrounding the
vibrissae. Three Mg concentrations were used: 0.04%,
0.22%, and 1.10%. The lowest two Mg concentrations
resembled the concentrations of our baseline diet (0.05%)
and of our 4×Ca, 4×Mg diet (0.2%). In contrast to our
study, they did not find a significant difference in
calcification between these two concentrations. This may
be due to the relative short duration of their diet period,
compared to our study. An important finding was that their
highest Mg concentration (1.10%) completely prevented
calcification during the 8-week diet period. Since our
highest concentration was 0.2%, this extends our findings.
It underscores the importance of further studies to establish
the optimal Mg concentration and to determine the
dependence of the effect on other factors, such as calcium
and phosphate levels, as well as diet duration. In addition to
these findings on Abcc6 knockout mice, also diet studied on
DCC susceptible mice demonstrated an influence of dietary
Mg on ectopic calcification [25].
The mechanism by which dietary magnesium exerts its
influence on ectopic calcification is currently unclear.
Magnesium ions function as co-factor in over 300 enzy-
matic reactions [23]. For a number of obvious mechanisms,
we found no support in our data: For example, magnesium
can bind phosphate, but we did not observe changes in
plasma phosphate levels as result of higher magnesium
intake. Alternatively, magnesium is a competitor of calcium
and may substitute for Ca
2+ in the crystal lattice, causing
crystal poisoning [26]. For such a direct effect, the local
magnesium concentrations clearly are of importance. We
found indeed that the high Ca high Mg diet increased the
plasma magnesium level, but no correlation between
plasma magnesium levels and calcifications in the kidney
was apparent. Finally, magnesium may also influence
calcification by suppressing parathyroid hormone (PTH)
secretion. As PTH is an important regulator of calcium
homeostasis, LaRusso et al. [24] measured plasma PTH
concentrations in Abcc6
−/− mice in their dietary interven-
tion study. However, high magnesium intake apparently did
not change PTH levels.
While the present study shows that dietary magnesium
modulates PXE severity in Abcc6
−/− mice, it should be
pointed out that we have no indications that a disturbed
magnesium level is cause or part of the etiology of PXE.
The present study as well as a previous study revealed no
difference in plasma Mg levels between Abcc6
−/− and wild-
type mice [13]. Therefore, we have no concrete indications
that the ABCC6 protein is directly involved in (co-)transport
of magnesium.
Other dietary factors and PXE
The effectofdietary phosphorushas beenstudied inAbcc6
−/−
mice as well as in DCC susceptible mice. In Abcc6
−/− mice,
no significant effect was demonstrated, nor did the use of
phosphate binders produce a clear effect [24, 27]. However,
a high phosphorus diet exacerbated the DCC phenotype [25].
Probably, the combination of minerals in the food plays an
important role as the most severe calcifications were found in
DCC mice that received the combination of low magnesium
and high phosphorus [25]. Interestingly, a study on PXE
Table 2 Plasma minerals (mmol/L ± SD) in Abcc6
−/− and wild-type mice after 7 months of diet













Data of wild-type and Abcc6
−/− mice were pooled since there was no difference between the genotypes
aSignificant (P<0.05) differences between the baseline diet and the other two diets
bSignificant differences (P<0.05) between 4×Ca, 4×Mg diet and other two diets
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oral phosphate binder may halt or reverse calcification in
some patients [28].
Other dietary factors that have been studied in relation to
DCC are dietary fluoride and dietary fat concentrations.
Excessive fluoride consumption reduced pathological cal-
cifications in the DCC mice [29]. The involvement of
dietary fat in the DCC pathology is controversial. In one
study, a high fat diet apparently did not affect calcification
[30], but other studies suggest that a high fat content in the
diet aggravates this phenotype [31, 32]. The possible effect
of dietary fat is particularly interesting since we noticed that
HDL-cholesterol level was decreased in the Abcc6
−/− mice.
We have found this before [13], but failed to reproduce this
observation in plasma of PXE patients (unpublished
results), so the relation with PXE pathology is at present
unclear. The mouse model may differ in this aspect from
the human situation.
In conclusion, while serum mineral balance in PXE is
not altered, the findings on the Abcc6
−/− mouse and on the
DCC susceptible mouse suggest that cardiovascular fea-
tures of PXE can be effectively modulated by dietary
minerals. The task ahead of us now is to elaborate the
formula of the optimal diet: a diet which maximizes the
reduction of ectopic calcification while minimizing adverse
effects of toxicity and osteoporosis. The Abcc6
−/− mouse
can be of great value for testing and design of such a diet.
In addition, by examining old mice and extending the diet
duration to more than 1 year, this animal model may also
give an indication of the effect of dietary minerals on the
calcification that occurs in the skin and eye of PXE
patients.
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